Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.
Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.
Medicenna Therapeutics (NASDAQ: MDNA) has received FDA approval for a hybrid registration trial design for its MDNA55 treatment targeting recurrent glioblastoma (rGBM). This innovative approach will use matched external controls for two-thirds of the control arm, reducing participant enrollment and trial costs while expediting regulatory approval. The design aims to generate robust overall survival data, potentially setting a new precedent for oncology trials. With previous promising results, the company looks to advance its partnership strategy for future development.